Percutaneous microwave ablation for benign focal liver lesions: Initial clinical results

Cheng,Zhigang; Liang,Ping; Yu,Xiaoling; Han,Zhiyu; Liu,Fangyi; Yu,Jie; Li,Xin

doi:10.3892/ol.2016.5409

Percutaneous microwave ablation for benign focal liver lesions: Initial clinical results

Authors:
- Zhigang Cheng
- Ping Liang
- Xiaoling Yu
- Zhiyu Han
- Fangyi Liu
- Jie Yu
- Xin Li
View Affiliations

Affiliations: Department of Interventional Ultrasound, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: November 22, 2016 https://doi.org/10.3892/ol.2016.5409
Pages: 429-434

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Benign focal liver lesions (BFLLs) have become a common disease diagnosed in the clinical setting following the advancement of imaging techniques. The aim of the present study was to evaluate the safety and clinical outcomes of percutaneous microwave (MW) ablation, guided by ultrasound (US), for the treatment of BFLLs. Between May 2005 and January 2011, 44 BFLLs (mean maximum diameter, 33.9±13.1 mm) in 37 patients (23 women and 14 men) were treated by US‑guided percutaneous MW ablation with cooled‑shaft antennae. The pathological diagnosis of a BFLL was confirmed in 91.9% (34/37) of patients using a US‑guided core needle biopsy prior to ablation. The BFLLs in the other 3 cases were diagnosed by typical presentations on contrast‑enhanced imaging, as the patients refused to undergo biopsies. Five inclusion criteria, including indeterminate diagnoses of nodules on contrast‑enhanced imaging prior to pathological verification, were recommended. The median follow‑up period was 27.0 months (range, 6‑73 months). The mean MW ablation energy and time were 55.0±41.6 kJ (range, 13.5‑207 kJ) and 1,039.9±706.2 sec (range, 270‑3,450 sec) per lesion, respectively. In total, 40 nodules (90.9%) were completely ablated, and no evidence of recurrence was demonstrated on contrast‑enhanced imaging follow‑up. The other 4 nodules (9.1%) were partially ablated due to the proximity of adjacent vital organs. Minor complications without sequelae included local pain and transient hemoglobinuria and no major complications occurred in peri‑ablation. Overall, US‑guided percutaneous MW ablation is a safe, effective and minimally invasive therapy for BFLLs in selected patients who are non‑surgical candidates.

View Figures

View References

1	Bartolotta TV, Midiri M, Galia M, Rollandi GA, Cademartiri F, Lagalla R and Cardinale AE: Characterization of benign hepatic tumors arising in fatty liver with SonoVue and pulse inversion US. Abdom Imaging. 32:84–91. 2007. View Article : Google Scholar : PubMed/NCBI
2	Petri A, Höhn J, Kókai EL, Savanya GK and Lázár G: Surgery of benign liver tumors: Indications for treatment: Twenty years' experience. Hepatogastroenterology. 55:592–595. 2008.PubMed/NCBI
3	Tanabe KK: The past 60 years in liver surgery. Cancer. 113:(Suppl). S1888–S1896. 2008. View Article : Google Scholar
4	Feng ZQ, Huang ZQ, Xu LN, Liu R, Zhang AQ, Huang XQ, Zhang WZ and Dong JH: Liver resection for benign hepatic lesions: A retrospective analysis of 827 consecutive cases. World J Gastroenterol. 14:7247–7251. 2008. View Article : Google Scholar : PubMed/NCBI
5	Srivastava DN, Gandhi D, Seith A, Pande GK and Sahni P: Transcatheter arterial embolization in the treatment of symptomatic cavernous hemangiomas of the liver: A prospective study. Abdom Imaging. 26:510–514. 2001. View Article : Google Scholar : PubMed/NCBI
6	Cui Y, Zhou LY, Dong MK, Wang P, Ji M, Li XO, Chen CW, Liu ZP, Xu YJ and Zhang HW: Ultrasonography guided percutaneous radiofrequency ablation for hepatic cavernous hemangioma. World J Gastroenterol. 9:2132–2134. 2003. View Article : Google Scholar : PubMed/NCBI
7	Hinshaw JL, Laeseke PJ, Weber SM and Lee FT Jr: Multiple-electrode radiofrequency ablation of symptomatic hepatic cavernous hemangioma. AJR Am J Roentgenol. 189:W146–W149. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ahmed M and Goldberg SN: Thermal ablation therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 13:S231–S244. 2002. View Article : Google Scholar : PubMed/NCBI
9	Wright AS, Sampson LA, Warner TF, Mahvi DM and Lee FT Jr: Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 236:132–139. 2005. View Article : Google Scholar : PubMed/NCBI
10	Liu FY, Yu XL, Liang P, Wang Y, Zhou P and Yu J: Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. Int J Hyperthermia. 26:448–455. 2010. View Article : Google Scholar : PubMed/NCBI
11	National Cancer Institute, . Cancer therapy evaluation program: Common Toxicity Criteria, version 2.0. http://ctep.cancer.gov/reporting/ctc.htmlAccessed July 1, 2005.
12	Arnoletti JP and Brodsky J: Surgical treatment of benign hepatic mass lesions. Am Surg. 65:431–433. 1999.PubMed/NCBI
13	Deutsch GS, Yeh KA, Bates WB III and Tannehill WB: Embolization for management of hepatic hemangiomas. Am Surg. 67:159–164. 2001.PubMed/NCBI
14	Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, Xu ZF, Liu GJ and Zheng YL: Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: A retrospective comparative study. J Gastroenterol. 40:1054–1060. 2005. View Article : Google Scholar : PubMed/NCBI
15	Vokaer B, Kothonidis K, Delatte P, De Cooman S, Pector JC and Liberale G: Should ruptured liver haemangioma be treated by surgery or by conservative means? A case report. Acta Chir Belg. 108:761–764. 2008. View Article : Google Scholar : PubMed/NCBI
16	Aiura K, Ohshima R, Matsumoto K, Ishii S, Arisawa Y, Nakagawa M and Noga K: Spontaneous rupture of liver hemangioma: Risk factors for rupture. J Hep Bil Pancr Surg. 3:308–312. 1996. View Article : Google Scholar
17	Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD III, Dupuy DE, Gervais DA, Gillams AR, Kane RA, Lee FT Jr, et al: Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-guided Tumor Ablation: Image-guided tumor ablation: Standardization of terminology and reporting criteria. J Vasc Interv Radiol. 20:(Suppl). S377–S390. 2009. View Article : Google Scholar : PubMed/NCBI
18	Liang P, Wang Y, Yu X and Dong B: Malignant liver tumors: Treatment with percutaneous microwave ablation-complications among cohort of 1136 patients. Radiology. 251:933–940. 2009. View Article : Google Scholar : PubMed/NCBI
19	Terkivatan T, de Wilt JH, de Man RA, van Rijn RR, Zondervan PE, Tilanus HW and Jzermans JN: Indications and long-term outcome of treatment for benign hepatic tumors: A critical appraisal. Arch Surg. 136:1033–1038. 2001. View Article : Google Scholar : PubMed/NCBI
20	Cardinal J, de Vera ME, Marsh JW, Steel JL, Geller DA, Fontes P, Nalesnik M and Gamblin TC: Treatment of hepatic epithelioid hemangioendothelioma: A single-institution experience with 25 cases. Arch Surg. 144:1035–1039. 2009. View Article : Google Scholar : PubMed/NCBI
21	Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C and Ma J: Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: A meta-analysis. J Cancer Res Clin Oncol. 140:199–210. 2014. View Article : Google Scholar : PubMed/NCBI